Lighthouse Investment Partners LLC Has $4.92 Million Holdings in Medtronic PLC $MDT

Lighthouse Investment Partners LLC grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 106.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 51,700 shares of the medical technology company’s stock after purchasing an additional 26,700 shares during the quarter. Lighthouse Investment Partners LLC’s holdings in Medtronic were worth $4,924,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Integrated Wealth Concepts LLC grew its holdings in Medtronic by 4.0% in the third quarter. Integrated Wealth Concepts LLC now owns 54,498 shares of the medical technology company’s stock worth $5,190,000 after purchasing an additional 2,072 shares during the period. Iron Triangle Partners LP raised its holdings in shares of Medtronic by 13.3% during the third quarter. Iron Triangle Partners LP now owns 453,347 shares of the medical technology company’s stock valued at $43,177,000 after purchasing an additional 53,347 shares during the period. JPL Wealth Management LLC acquired a new position in shares of Medtronic during the third quarter valued at about $40,000. Hilltop Holdings Inc. boosted its position in shares of Medtronic by 12.7% during the 3rd quarter. Hilltop Holdings Inc. now owns 17,875 shares of the medical technology company’s stock worth $1,702,000 after purchasing an additional 2,008 shares in the last quarter. Finally, Gotham Asset Management LLC grew its stake in shares of Medtronic by 11.7% in the 3rd quarter. Gotham Asset Management LLC now owns 288,010 shares of the medical technology company’s stock valued at $27,430,000 after buying an additional 30,129 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of Medtronic stock opened at $88.13 on Tuesday. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The business has a 50 day moving average price of $97.77 and a 200-day moving average price of $96.88. The company has a market cap of $113.15 billion, a PE ratio of 24.55, a price-to-earnings-growth ratio of 2.24 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. Medtronic’s dividend payout ratio is currently 79.11%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Citigroup started coverage on Medtronic in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 target price for the company. Robert W. Baird cut their price target on Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Needham & Company LLC reissued a “buy” rating and issued a $120.00 price objective on shares of Medtronic in a research note on Tuesday, March 10th. Leerink Partners reaffirmed an “outperform” rating and set a $119.00 target price on shares of Medtronic in a research report on Tuesday, March 10th. Finally, Mizuho upgraded Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $110.74.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is owned by insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).